ABSTRACT
A new and efficient synthetic route for dual-Src/Abl kinase inhibitor dasatinib (Sprycel®), an anticancer drug, is described. This commercially viable process yields dasatinib monohydrate free of potential impurities with consistent yield of 68% in route A and 61% in route B with HPLC purity >99.80% over four stages.
GRAPHICAL ABSTRACT
![](/cms/asset/9fdb7c55-da8d-407b-b5e5-a70882a51b6e/lsyc_a_1337150_uf0001_oc.jpg)